An amplified signal imaging software for prognosis of cancer enabling the evaluation of clinical efficiency of personalised cancer treatments to an unprecedented level.

Informazioni relative al progetto

iaFRET

ID dell’accordo di sovvenzione: 807316

DOI

10.3030/807316

Progetto chiuso

Data della firma CE 13 Febbraio 2018

Data di avvio 1 Febbraio 2018

Data di completamento 30 Aprile 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

FASTBASE SOLUTIONS SOCIEDAD LIMITADA
Spain

Periodic Reporting for period 1 - iaFRET (An amplified signal imaging software for prognosis of cancer enabling the evaluation of clinicalefficiency of personalised cancer treatments to an unprecedented level.)

Periodo di rendicontazione: 2018-02-01 al 2018-04-30

Sintesi del contesto e degli obiettivi generali del progetto

Current cancer prognosis technologies are highly inaccurate and treatments do not support patient stratification. This leads to negative outcomes as treatments like chemotherapy are simply set to the highest tolerable dose and administered to patients who may not respond at all (up to 75% of cancer patients do not respond to drugs). Our iaFRET platform can examine how proteins act right down to the molecular scale, including how cancer cells are communicating and engaging with one another. This allows staging and grading of the cancer, and analysis of whether it is the original tumor site or a metastasis. It can also assess whether the cancer cells respond to drugs, and the proportion of cells that are resistant. This will allow treatments to be adjusted based on the patient's cancer, and as a companion to new diagnostics, should dramatically improve the survival rate of patients receiving chemotherapy and other treatments. Our overall objectives with the project are to bring our prognosis platform to the market with a lung cancer testing process first, and then to move on to other cancer types.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

We assessed and validated our business model through research with internal resources and outreach to major stakeholders in the future of our product. These included clinical research organisations, certification and regulation experts, and a cancer research and treatment institute to host our clinical trial. We assessed the market and forces driving growth in cancer research, concluding that not only is there significant business opportunity for us, but a major opportunity to improve clinical cancer care throughout Europe - this will have critical impacts on future EU health objectives, as Europe, despite having only ~12.5% of the world's population, carries about 25% of the world's cancer burden.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We have observed that our platform is significantly more accurate than existing, competing cancer prognostic systems and technologies. We want to quantify this to a 95-99% reduction in false positives, and to support early identification of non-responders or patients with drug-resistant tumours. This can then let hospitals customise treatment to the patient's condition, and whether their cancer is responding to the treatment. Once we achieve marketing authorisation, we can then use the platform to validate tests for other cancer types, and even other diseases with known biomarkers such as diabetes and Alzheimer's Disease.

iaFRET in use.